Kamada (NASDAQ:KMDA) Shares Cross Below 200-Day Moving Average of $5.46

Shares of Kamada Ltd. (NASDAQ:KMDA) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $5.46 and traded as low as $5.06. Kamada shares last traded at $5.10, with a volume of 7,991 shares changing hands.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. StockNews.com raised Kamada from a “hold” rating to a “buy” rating in a research report on Thursday, January 4th. HC Wainwright reissued a “buy” rating and set a $11.00 price target on shares of Kamada in a research report on Thursday, March 7th.

Kamada Price Performance

The company has a 50-day moving average price of $5.72 and a two-hundred day moving average price of $5.46. The company has a market cap of $297.69 million, a PE ratio of 34.53 and a beta of 1.04.

Kamada (NASDAQ:KMDA) last issued its earnings results on Wednesday, March 6th. The biotechnology company reported $0.09 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.04. Kamada had a return on equity of 5.66% and a net margin of 5.81%. The company had revenue of $36.43 million during the quarter, compared to the consensus estimate of $37.71 million. On average, equities research analysts anticipate that Kamada Ltd. will post 0.23 earnings per share for the current year.

Institutional Investors Weigh In On Kamada

Several institutional investors and hedge funds have recently modified their holdings of the stock. Meitav Investment House Ltd. boosted its position in shares of Kamada by 17.2% in the third quarter. Meitav Investment House Ltd. now owns 76,835 shares of the biotechnology company’s stock worth $412,000 after buying an additional 11,284 shares during the period. EWA LLC acquired a new position in shares of Kamada in the fourth quarter worth about $68,000. Y.D. More Investments Ltd acquired a new position in shares of Kamada in the third quarter worth about $75,000. Aristides Capital LLC lifted its stake in shares of Kamada by 41.6% in the fourth quarter. Aristides Capital LLC now owns 56,635 shares of the biotechnology company’s stock worth $347,000 after acquiring an additional 16,635 shares in the last quarter. Finally, Calton & Associates Inc. acquired a new position in shares of Kamada in the fourth quarter worth about $111,000. Hedge funds and other institutional investors own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.